Biotech Hangout

→ WHAT IT COVERS Biotech Hangout Episode 194 covers the XBI's 80% twelve-month rally, Moderna's mRNA cancer vaccine phase three success in melanoma, Revolution Medicines' FDA approval for pancreatic cancer at $478,000 annually, the Heidi Overton FDA commissioner nomination, ATTR cardiomyopathy gene silencer data failure, and escalating drug pricing concerns across newly approved therapies. → KEY INSIGHTS - **Biotech M&A vs.

→ WHAT IT COVERS Biotech Hangout Episode 193 covers XBI market performance, two high-profile clinical failures (10x Genomics HFpEF trial, Siona CF trial), the Jazz Pharmaceuticals $1.3B Actio acquisition, positive psychedelics phase three data from Definium, and the ongoing US-China biotech protectionism debate. → KEY INSIGHTS - **Biotech Market Bifurcation:** XBI outperforms the broader market year-to-date, but returns are highly uneven.

→ WHAT IT COVERS Biotech Hangout Episode 192 covers Q2 earnings season performance across biotech, the AstraZeneca-Bristol Myers merger speculation, 17 IPOs in 2026 with strong post-debut trading, reverse merger trends, FDA regulatory decisions on Miriam and Praxis drugs, Replimmune's approval, and US-China clinical trial competitiveness concerns raised by Strand CEO Jake Beecroft.

→ WHAT IT COVERS Biotech Hangout Episode 191 covers Q2 2026 biotech sector performance with XBI up 24% year-to-date, reverse merger trends, AI's role in drug discovery, major BD deals including J&J's $785M Sail Biomedicines partnership and argenx's $2.2B Forte acquisition, FDA advisory committee outcomes, and Alnylam's guidance cut on Amvutra. → KEY INSIGHTS - **Biotech Sector Positioning:** XBI is up 24% year-to-date versus S&P 500 at 9% and Nasdaq at 8%, with three structural tailwinds...

→ WHAT IT COVERS Biotech Hangout Episode 190 covers the reopening IPO window via Scribe Therapeutics' early-stage $120M offering, reverse merger financing trends, Colossal Biosciences' $20-30B valuation round, the MX Biopharma CMO fraud scandal, DYNE Therapeutics' DMD BLA acceptance, and two upcoming FDA AdCom panels for Replimmune and Capricor. → KEY INSIGHTS - **Early-Stage IPO Signal:** When biotech markets peak, risk tolerance expands and earlier-stage companies access public markets —...

→ WHAT IT COVERS Biotech Hangout Episode 189 covers Eli Lilly's $3.8B Atai acquisition, Roivant's upcoming brepacitinib launch for dermatomyositis, China's rising first-in-class drug innovation, Kalshi's clinical trial betting markets, Merck's oral PCSK9 inhibitor approval, and Biogen's mixed Phase 2 tau-targeting ASO data in Alzheimer's disease. → KEY INSIGHTS - **Eli Lilly's expansion strategy:** Lilly's acquisition of Atai for $2.

→ WHAT IT COVERS Biotech Hangout Episode 188 covers FDA regulatory shifts including CRL transparency rollbacks and lowered approval bars for rare diseases, the failed AstraZeneca/Ionis eplontersen TTR cardiomyopathy trial, Vertex's $9B Crinetics acquisition, Anthropic's Claude for Science AI platform, and upcoming Biogen anti-tau Alzheimer's data at AAIC London.

→ WHAT IT COVERS Biotech Hangout Episode 187 covers the XBI rally from 130 to 155-160, AbbVie's $10.9B Apogee acquisition, China asset spin-out transactions including Sarafa and Olin Biosciences, FDA normalization under potential new commissioners, oncology investment challenges, and clinical data updates across HS, psychedelics, and androgenic alopecia. → KEY INSIGHTS - **XBI Valuation Framework:** Pharma free cash flow years-to-acquire all SMID-cap biotech sits at 3.7x in 2026, up from 3.

→ WHAT IT COVERS Biotech Hangout Episode 186 covers mid-2026 biotech market performance, with XBI up 10.5% year-to-date, a record $771M Parabolas IPO, GSK's $10.9B acquisition of Nuvialent, Tango's 90%+ response rate PRMT5 inhibitor data in pancreatic cancer, and the evolving IPO and M&A landscape for private biotech companies. → KEY INSIGHTS - **IPO Market Calibration:** Biotech has produced roughly 12 IPOs by mid-2026, collectively raising over $4B, with the XBI outperforming the S&P 500 by...

→ WHAT IT COVERS Biotech Hangout Episode 185 covers ASCO 2026 highlights including PD-1/VEGF bispecifics, RAS inhibitor breakthroughs in pancreatic cancer, CDK4-selective inhibitors in breast cancer, GRAIL's multi-cancer detection trial failure, Abivax's ulcerative colitis safety signal, in vivo CAR-T early data, and the COINS Act debate over US-China biotech investment restrictions.

→ WHAT IT COVERS Biotech Hangout Episode 184 covers the 2026 IPO market health with 11 filings by May, Ginkgo Bioworks CEO Jason Kelly's national security argument against offshoring biotechnology to China, Eli Lilly's three vaccine acquisitions totaling $3.8B, and key ASCO oncology data previews including Revolution Medicines' pancreatic cancer results. → KEY INSIGHTS - **Biotech IPO benchmark:** Eleven biotech IPOs filed by end of May 2026 already matches or exceeds all of 2025's total.

→ WHAT IT COVERS Biotech Hangout Episode 183 covers Bristol Myers Squibb's $950M upfront deal with Hengrui, China's growing competitive threat to US biotech innovation, Isomorphic Labs' $2.25B Series B raise, FDA Commissioner Marty Makary's resignation, and upcoming data catalysts at ASCO, ADA, and ATS conferences across oncology and respiratory disease.

→ WHAT IT COVERS Biotech Hangout Episode 182 covers a record-breaking Q1 2026 secondary offering environment, three new M&A deals totaling over $6 billion, FDA leadership instability under Commissioner Makary, clinical data from Cytokinetics, Artiva, and J&J, and the accelerating influence of Chinese biotech assets on U.S. drug development pipelines.

→ WHAT IT COVERS Biotech Hangout Episode 181 covers May 2026 biotech market performance, with the XBI up 8% year-to-date outperforming the S&P 500 by 300 basis points. Hosts analyze 10 IPOs totaling $3.2 billion, major M&A activity led by Eli Lilly's six acquisitions, Revolution Medicines' pancreatic cancer phase three data, and Harmony Three's failed interim PFS analysis. → KEY INSIGHTS - **Biotech IPO Market Quality:** Ten biotech IPOs have raised $3.

→ WHAT IT COVERS Biotech Hangout Episode 180 covers the XBI reaching post-pandemic highs, Kilera's $625M IPO, Revolution Medicines' pancreatic cancer data showing a 0.4 overall survival hazard ratio, Allogene's allogeneic CAR-T results, Spire's UC data, and the FDA's approval of sparsentan for FSGS despite a failed eGFR endpoint. → KEY INSIGHTS - **XBI Construction Shift:** The XBI's methodology has moved away from equal-weight across broad stocks toward weighting larger, more liquid companies.

→ WHAT IT COVERS Biotech Hangout Episode 179 covers biotech market performance with XBI up 84% year-over-year, Merck's $6.7B Terns acquisition backstory, Gilead's $3.15B Tubulus ADC platform deal, Neurocrine's $3B Soleno purchase, FDA regulatory developments, and new obesity drug approvals from Novo Nordisk and Eli Lilly. → KEY INSIGHTS - **Biotech Market Outperformance:** The XBI ETF hit a 52-week high near 132, delivering an 84% return over the past year versus 30% for the S&P 500 and 39% for...

→ WHAT IT COVERS Biotech Hangout Episode 178 covers Q1 2026 biotech market performance, three major M&A deals (Biogen/Apellis at $5.6B, Eli Lilly/Centessa at $6B, Cyclerion/Corsana reverse merger), FDA regulatory shifts favoring orphan drugs, Lilly's oral GLP-1 approval, blood-brain barrier shuttle technology momentum, and competitive dynamics in obesity, narcolepsy, and sickle cell disease markets. → KEY INSIGHTS - **Biotech Sector Outperformance:** XBI is up 7.

→ WHAT IT COVERS Biotech Hangout Episode 177 covers the week of March 27, 2026, examining roughly $10 billion in M&A activity including Gilead's $2.2 billion Ouro acquisition and Merck's $6 billion Tern deal, alongside FDA regulatory shifts post-Vinay Prasad, and clinical data from Beam, Sarepta, and Maze Therapeutics. → KEY INSIGHTS - **Biotech relative performance:** XBI is up approximately 2% year-to-date while the S&P 500 is down 6%, an 8-percentage-point spread in three months.

→ WHAT IT COVERS Biotech Hangout Episode 176 covers macroeconomic risks from Middle East conflict driving oil toward $100/barrel, Vinay Prasad's FDA departure, Servier's $2.5B Day One acquisition, phase three data from Roche and Xenon, IDEA Biosciences' upcoming uveal melanoma readout, and competitive dynamics in NMIBC, IgAN, and obesity markets. → KEY INSIGHTS - **Biotech macro resilience:** Rising oil prices near $100/barrel and potential inflation-driven rate increases pose sector risk, but...

→ WHAT IT COVERS Biotech Hangout Episode 175 covers Q1 2026 biotech capital markets recovery, the $2.25B Roivant-Moderna lipid nanoparticle patent settlement, FDA controversy surrounding UniCure's filing rejection, GLP-1 obesity drug market expansion projections, and the growing concentration of biotech investment conferences in Miami each March. → KEY INSIGHTS - **Biotech IPO Recovery:** Q1 2026 is on pace to reach $2.